Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 3/20 | 0.40 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.40 |
| ▸ | CD38 | P28907 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517136 | 1.00 | LATS1 (0.40) | LATS1LATS2CD38JAK3JAK2 | |
| SCHEMBL19857319 | 1.00 | LATS1 (0.40) | LATS1LATS2CD38JAK3JAK2 | |
| SCHEMBL22787381 | 0.86 | JAK2 (0.43) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL19857412 | 0.86 | JAK2 (0.43) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL22787375 | 0.86 | JAK2 (0.43) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL24669670 | 0.86 | JAK2 (0.43) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL22787377 | 0.85 | JAK2 (0.42) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL22787376 | 0.85 | JAK2 (0.42) | LATS1LATS2JAK2MERTKJAK1 | |
| SCHEMBL2553480 | 0.83 | KMT2A (0.49) | JAK3JAK2MERTKJAK1MEN1 | |
| SCHEMBL574174 | 0.82 | KMT2A (0.51) | JAK3JAK2MERTKJAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | LATS1 2644/4885LATS2 3105/4885CD38 509/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | LATS1 2688/4885LATS2 3106/4885CD38 529/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | LATS1 2688/4885LATS2 3106/4885CD38 529/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | LATS1 2688/4885LATS2 3106/4885CD38 529/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | LATS1 2688/4885LATS2 3106/4885CD38 529/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | LATS1 2688/4885LATS2 3106/4885CD38 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.